Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 3, 2019 (Earliest event reported: April 2, 2019)
Context: The Company is an emerging growth company incorporated in Nevada. This filing reports a corporate event under Item 8.01 (Other Events).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding a specific corporate event rather than a periodic financial report.
Material Changes
No material financial changes or operational updates are reported in this filing. The sole material event is the announcement of a ceremonial activity.
Outlook, Commentary, and Risks
Management Commentary: On April 2, 2019, the Company announced that its CEO (Raymond J. Tesi), CFO (David Moss), and CSO (Professor Mark Lowdell), along with other management team members, will ring the NASDAQ closing bell on Tuesday, April 9, 2019.
Risks and Contingencies: No risks, contingencies, or unusual items are disclosed in this specific filing.
Investor Verification Checklist
- Verify the date of the NASDAQ closing bell ceremony (April 9, 2019).
- Confirm the identities of the management team members participating in the event.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.